Siemens Mobility names Beatrice Bock as incoming CFO

Veronika Bienert CFO Siemens Financial Services
Veronika Bienert CFO - Siemens Financial Services
0Comments

Karl Blaim will step down from his role as CFO and Managing Director of Siemens Mobility at the end of November 2025, after a 40-year tenure with Siemens. He leaves to pursue new professional opportunities. Beatrice Bock, currently Chief Risk Officer for the Equity Finance Business Unit at Siemens Financial Services GmbH, has been appointed as his successor.

Roland Busch, President and CEO of Siemens AG and Chairman of the Supervisory Board of Siemens Mobility, stated: “By bringing Beatrice Bock on board, we are appointing a highly qualified leader from within our own ranks to take on these substantial responsibilities. Her extensive experience in financial strategy and risk management is invaluable, particularly in such a challenging economic environment. Together with Michael Peter, an outstanding CEO in the mobility business, she will continue Siemens Mobility’s ongoing strategic development and will further strengthen our position as a technology leader in the transportation industry.” He also expressed gratitude to Karl Blaim: “On behalf of the Managing Board of Siemens AG, I would like to thank Karl Blaim for 40 years of service to Siemens, including many years in senior leadership roles at Siemens Mobility. With his personal commitment, he has contributed to the success of Siemens Mobility and has given our transportation business direction in difficult times.”

Michael Peter, CEO and Managing Director of Siemens Mobility, acknowledged Blaim’s impact: “Karl Blaim has been instrumental in driving the successful further development of Siemens Mobility. After our carve-out, he shaped the strategic realignment and successfully steered the business onto a profitable growth trajectory.” Peter also welcomed Bock’s appointment: “At the same time, my heartfelt congratulations go to Beatrice Bock on her new role as CFO and Managing Director. I’m looking forward to working together with her, and I’m convinced that her experience and expertise will enable Siemens Mobility to continue to develop successfully as a company.”

Beatrice Bock commented on her appointment: “It’s a great joy for me to take on responsibility for Siemens Mobility as CFO and Managing Director. This multifaceted and dynamic field of business is characterized by important infrastructure projects that are making rail transportation sustainable for future generations. A special thank you goes to Roland Busch and to the entire Siemens Managing Board for the trust they’ve placed in me. I’m looking forward to beginning Siemens Mobility’s next chapter together with Michael Peter.”

Bock joined Siemens in corporate finance in 2010. She has held various positions at both Siemens Mobility and Siemens Energy before joining Siemens Financial Services’ Equity Finance Business Unit in 2022 as Chief Financial Officer; she became Chief Risk Officer there in 2024. She holds a Master of Science degree from Bayes Business School.

Reflecting on his departure, Karl Blaim said: “My 18 years as CFO of Siemens Mobility have been an enriching time. Leading the company through growth and transformation has been a privilege. With a strong team in place, now is the right moment for a leadership change to make room for new energy. Personally, I look forward to taking on further challenges and opening a new professional chapter.”



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.